Embodiments provide a polycyclic compound and a light emitting element that includes the polycyclic compound. The light emitting element includes a first electrode, a second electrode disposed on the first electrode, and at least one functional layer disposed between the first electrode and the second electrode, wherein the at least one functional layer includes the polycyclic compound, which is represented by Formula 1. Formula 1 is defined in the specification. The light emitting element exhibits a long service life.

##STR00001##

A light-emitting device includes: a first electrode; a second electrode facing the first electrode; and an interlayer between the first electrode and the second electrode and including an emission layer, wherein the emission layer includes at least one organometallic compound represented by Formula 1:

##STR00001##

wherein Formula 1 is the same as described herein.

An organometallic compound represented by Formula 1:

M.sub.1(Ln.sub.1).sub.n1(Ln.sub.2).sub.n2  Formula 1

wherein M.sub.1 is a transition metal, Ln.sub.1 is a ligand represented by Formula 1A, Ln.sub.2 is a ligand represented by Formula 1B, n1 is 1 or 2, and n2 is 1 or 2,

##STR00001##

wherein ring CY.sub.1 and ring CY.sub.2 are each independently a C.sub.5-C.sub.30 carbocyclic group or a C.sub.1-C.sub.30 heterocyclic group, ring CY.sub.41 is a phenyl group, ring CY.sub.42 is a 5-membered aromatic heterocyclic group, and the other substituents are as described herein.

Provided are a compound capable of improving the light-emitting efficiency, stability, and lifespan of an element; an organic electronic element using same; and an electronic device thereof.

The disclosure provides at least one compound, reiterated derivative, or pharmaceutically acceptable salt chosen from compounds of formula (I), reiterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing, compositions comprising the same, and methods of making and using the same, including use in treating APOL1 mediated kidney disease.

##STR00001##

An organometallic compound represented by Formula 1:

M(L.sub.1).sub.n1(L.sub.2).sub.n2  Formula 1

wherein, M is a transition metal, L.sub.1 and L.sub.2 are ligands as provided herein, n1 and n2 are each independently 1 or 2, the sum of n1 and n2 is 2 or 3, and L.sub.1 is different from L.sub.2.

The disclosure provides compounds of Formula (I) ##STR00001##
or a pharmaceutically acceptable salt thereof, wherein W.sup.1, W.sup.2, Y, Z, M, L, C.sup.y, C.sup.z, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.2a, R.sup.y, R.sup.z and the subscripts m, n, q, and r are as described herein. The compounds or their pharmaceutically acceptable salts can inhibit the G12C mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.

To provide a compound for further improving the capability of an organic EL device, an organic electroluminescent element having a further improved device capability, and an electronic device including the organic electroluminescent element. Disclosed are a compound represented by the following formula (1) or formula (2) (wherein each symbol in each formula is as defined in the description), an organic electroluminescent element containing the compound, and an electronic device including the organic electroluminescent element.

##STR00001##

Described herein are crystalline fumarate salts having a Formula I, pharmaceutical formulations comprising the same, methods for their production, and uses thereof, Formula I comprising: ##STR00001##
wherein each R.sup.1 is independently selected from protium and deuterium; each R.sup.2 is independently selected from protium and deuterium; each R.sup.3 is independently selected from protium and deuterium; and each R.sup.4 is independently selected from protium and deuterium; and wherein the compound has a PXRD pattern comprising characteristic peaks at 19.2±0.2 and 24.7±0.2 degrees 2-theta.

An organic electroluminescence device inducting a cathode, an anode, and an emitting layer disposed between the cathode and the anode, wherein the emitting layer includes a compound represented by the following formula (1) and one or more compounds selected from the group consisting of compounds represented by each of formulas (11), (21), (31), (41), (51), (61), (71) and (81). In the formula (1), at least one of R.sub.1 to R.sub.8 is a deuterium atom,

##STR00001##